key: cord-0862019-5h5srmu1
authors: Khan, A. A.; Sirsat, A. T.; Singh, H.; Cash, P.
title: Microbiota and cancer: current understanding and mechanistic implications
date: 2021-08-13
journal: Clin Transl Oncol
DOI: 10.1007/s12094-021-02690-x
sha: 080a13a14ce24f6cec34e60a54747a2934ff4707
doc_id: 862019
cord_uid: 5h5srmu1

During last few decades, role of microbiota and its importance in several diseases has been a hot topic for research. The microbiota is considered as an accessory organ for maintaining normal physiology of an individual. These microbiota organisms which normally colonize several epithelial surfaces are known to secrete several small molecules leading to local and systemic effects on normal biological processes. The role of microbiota is also established in carcinogenesis as per several recent findings. The effects of microbiota on cancer is not only limited to their contribution in oncogenesis, but the overall susceptibility for oncogenesis and its subsequent progression, development of coinfections, and response to anticancer therapy is also found to be affected by microbiota. The information about microbiota and subsequent contributions of microbes in anticancer response motivated researchers in development of microbes-based anticancer therapeutics. We provided current status of microbiota contribution in oncogenesis with special reference to their mechanistic implications in different aspects of oncogenesis. In addition, the mechanistic implications of bacteria in anticancer therapy are also discussed. We conclude that several mechanisms of microbiota-mediated regulation of oncogenesis is known, but approaches must be focused on understanding contribution of microbiota as a community rather than single organisms-mediated effects.

Recently a large number of studies are accumulating linking role of microbiota with normal host physiology and subsequent disease progression. The disruption of normal microbiota, known as microbiota dysbiosis contributes to development of several clinical conditions related to physical to behavioral aspects [1, 2] . Plethora of literature is supporting the role of microbiota in several physical abnormalities including, gastrointestinal, neurological to cardiovascular, etc. [3, 4] . Moreover, studies are linking role of microbiota with cancer and supporting its contribution in almost all aspect of carcinogenesis ranging from cancer susceptibility and progression to response for anticancer therapy [5, 6] . Literature is suggesting that correction of microbiota dysbiosis through beneficial probiotic bacteria can be beneficial in a large number of cancer types [7, 8] . In addition, several microbes have been found with anticancer potential and are being developed for effective anticancer therapy [9] .

Though, several complexities are creating bottlenecks in integrating such therapeutic modalities in routine anticancer management practices, multiple strategies are devised to utilize information obtained from microbiota-related experiments for management of cancer. These complexities including, geographical and inter individual variability of microbiota, identification of key microbiota component affecting carcinogenic process, and identification of proper mechanistic information leading to microbiota-mediated oncogenic transformation. Herein, we draw attention to the mechanistic implications of microbiota in influencing different aspects of oncogenesis and its subsequent influence on development of anticancer management strategies.

The role of microbiota in oncogenesis is widely recognized in a number of studies. It is estimated that more than 20% of cancer cases are associated with infectious agents [10] . Several microorganisms are specifically linked with development of cancer, like H, pylori which is declared as a class I carcinogen by the World Health Organization and involved in gastric adenocarcinoma and mucosa associated lymphoid tissue (MALT) lymphoma [11] . Chlamydia trachomatis, Escherichia coli, Salmonella enterica are also suspiciously involved in cervical, colorectal, and gallbladder cancer, respectively [12] [13] [14] [15] [16] [17] . In addition, microbiota dysbiosis involving modulation of several microbiota organisms is also linked with carcinogenesis [18] . The antibiotics-mediated microbial dysbiosis is also known to play important role in tumorigenesis in some recent studies [19] . Several mechanisms of microbiota dysbiosis-mediated tumorigenesis are also proposed recently ( Fig. 1 ), though the collective information about contribution of each microbiota components and their subsequent involvement in carcinogenesis is still lacking. Several studies are available indicating causal role of microbiota dysbiosis and cancer. For example, the microbiota of cancer-associated area is found to be different from microbiota occupying nearby healthy mucosa [20, 21] . Several articles are available on types of microbiota components modulation in different cancer, but their specific links with carcinogenesis needs more attention to understand their mechanistic implications. Following section indicates some mechanisms possibly involved in microbiota-mediated cancer etiology. Table 1 also lists some specific microbial components and their mechanistic involvement in carcinogenesis.

The gut microbiota is primarily involved in providing energy from non-digested food substances and therefore the dietary components are a major factor deciding microbiota composition. Under certain situations, these microbiota-mediated metabolic products have ability to influence carcinogenicity and these effects range from activation and synthesis of carcinogen, to removal of carcinogen [22] . Several bacterial enzymes are involved in cancer and indicate towards involvement of microbiota in carcinogenesis. Figure 1B   Fig. 1 Role of microbiota and individual microbiota components in carcinogenesis. The figure is divided in three sections and cancerassociated mechanisms are generally shown with red color while microbial components are shown with green color. Section A indi-cates influence of microbiota on cell growth or apoptosis related process, while section B and C indicate towards metabolic influence of microbiota and mechanisms associated with individual microbes on carcinogenesis, respectively represents microbiota enzymes and their metabolic influence on carcinogenesis. It is found that prebiotics are known to increase beneficial Bifidobacteria and suppress these carcinogen metabolizing enzymes activities [23] . The probiotics are beneficial bacteria known for their ability to provide several anticancer effects and a number of articles are available for anticancer effects of probiotics [7, 8] . Therefore increasing the number of beneficial bacteria through fecal microbiota transplant is a well-known strategy for management of several gastrointestinal ailments [24] . The role of metabolic influence of microbiota is also evident through strong influence of dietary pattern on carcinogenesis. The excess energy intake in comparison to normal requirement is suggested to be linked with human cancer [25] and microbiota plays important role in this process through regulation of metabolic process [26] . 

Development of cancer is directly linked with abnormal cell proliferation and it can be ranged from increased cellular proliferation to inhibition of cell death. The microbiota is known to regulate cell proliferation and regeneration under various conditions [27] . It has been found a long time ago that addition of dietary fiber in rat increases intestinal cell proliferation [28] . In addition, restriction of intestinal nutrients is known to induce intestinal atrophy even after providing nutrients through parenteral route [29] . The role of microbiota in digestion of dietary fiber and production of necessary metabolites indicate towards their involvement in regulating cell proliferation through this mechanism. It is known that certain bacterial fermentative metabolites, such as short chain fatty acid (SCFA) produced from nutrients are having ability to regulate cell proliferation [30, 31] . Several bacteria are known to produce certain proteins known as nucleomodulins with the ability to alter normal nuclear function and thereby influence cell growth. These nucleomodulins are also identified in bacteria suspiciously associated with cancer, thereby indicate towards potential involvement of these proteins in carcinogenesis [32] . In contrast, microbiota also has ability to both promote and inhibit cell death through regulating apoptosis and therefore contributing in intestinal mucosal epithelial cell inflammation and integrity [33] . It has been identified that germ free newborn mice has reduced interleukin 1β, tumor necrosis factor (TNF) and altered cell death [34] . Though this study was designed to evaluate effect of microbiota on brain development, but their results demonstrating microbiota-mediated regulation of major apoptotic regulator TNF demonstrate its ability to regulate cell death. Supporting this notion, probiotics bacteria Lactobacillus rhamnosus GG is able to inhibit cytokine-mediated apoptosis through activation of anti-apoptotic Akt/protein kinase B and inhibition of pro-apoptotic TNF, p38/MAPK, IL-1α or IFN-γ [35] . L. rhamnosus GG is also known to produce two proteins (p75 and p40) which activate Akt and promote colon epithelial cell growth and reduce TNF-mediated epithelial cell damage [36] . The pathogen associated molecular patterns (PAMP) of microbiota components are recognized through Toll like receptor (TLR) present on enterocytes and other surfaces to mount immunologic response. The toll-like receptor are known to show modulated expression during carcinogenesis and this is also considered to contribute in infectious complications among cancer patients [37] . The vice versa modulated TLR expression in response to different microbiota composition can also regulate cellular proliferation and death in multiple ways. The central TLR signaling pathways involving MAPK and PI3K play important role in regulating cell proliferation through TLR [38] . Figure 1A indicates different mechanisms through which microbiota can regulate cell proliferation and apoptosis.

Anticancer therapy used to manage cancer also creates several effects on host microbiota and therefore generate several associated complications. These effects are mediated through multiple mechanisms, including dietary alterations, necessary surgical interventions and use of antibiotics for preventing post-surgical and other infections in addition to effects caused by anticancer drugs [39] . Therefore the reverse effect of microbiota modulation on anticancer therapy is also gaining importance and studies are conducted to understand and utilize this attribute for improving anticancer therapy treatment outcomes. The recent concept of pharmacomicrobiomics is considering effects of microbiota in drug response including anticancer therapy [40] . A common antimetabolite methotraxate is used in a number of clinical diseases including cancers, it has been found to inhibit several representative gut bacteria and alter microbiota composition [41] . An in vivo study on gut microbiota of colorectal cancer mouse model showed that anticancer drug 5-Fluorouracil (5-FU) can change microbiota diversity and composition. In addition, antibiotics-mediated gut microbiota disruption also contributed to reduced antitumor efficacy of 5-FU [42] . An important anticancer drug cyclophosphamide is also known to alter composition of microbiota in intestine and promote certain gram positive bacterial translocation to secondary lymphoid organs, where these bacteria stimulate production of pathogenic Th17 cells Th1 response [43] . Several other anticancer drugs are known to cause diarrhea through multiple mechanisms including killing of beneficial bacteria helping in digestion [44] . In contrast, microbiota components are also known to alter the response toward chemotherapeutic drugs and have been reviewed extensively. Microbiota components are able to modulate anticancer therapy outcomes through multiple mechanisms including resistance to anticancer drugs and immune check points inhibitors, modulation of metabolism, etc. Therefore it is suggested that these microbiota organisms can also serve as a prognostic and diagnostic marker for cancer [45] . Several microbial components itself possess anticancer activity and it is mediated by multiple mechanisms. Some microbes are known for production of anticancer substances [46] , activation of antitumor immune response, and modulation of signaling pathways, etc. [6, 47] . Few bacteria known to possess anticancer activity are mentioned in Table 2 with their mechanistic implications.

In addition to above mentioned mechanisms, microbiota is also known to alter several important signaling pathways leading to progression or inhibition of cancer. Some of these signaling pathways are already discussed in earlier section, but some other bacteria-specific signaling events leading to carcinogenesis are mentioned in Fig. 1C . The signaling pathways are regulating multiple mechanisms contributing to carcinogenesis including immune regulation. Microbiota is known to mediate development and regulation of immune system and therefore it can influence outcome of anticancer immunotherapy [48] . The role of microbiota and probiotics are also proposed in management of inflammatory and cellular immune response in COVID-19 [49, 50] . Moreover, the role of immune regulation in cancer and its management is a widely studied aspect. Antibodies against CTLA-4 are successfully used in anticancer immunotherapy but its efficacy depends on gut microbiota organisms Bacteroides spp. [51] . The role of commensal bacteria in influencing anticancer activity of immunotherapy is also reviewed [52] and it was suggested that normal intestinal microbiota supports anticancer therapy while this attribute is missing with dysbiotic microbiota and inflammation regulation is considered as an important mechanisms in this process [53] . For more than one century, inflammation is considered as a key mechanism for carcinogenesis after detection of leukocytes in cancer tissues [54] . Recent studies are also finding strong links between chronic inflammation and cancer risk [55] . The microbiota components are known to up regulate several inflammatory cytokines and it has been reviewed in other articles [56] . Human functional genomics project indicated that fungal and bacterial agents are significantly associated with inflammatory cytokine response [57] . It is found that microbiota can promote cytokine production through engaging microbial metabolite sensor receptors that are highly expressed on inflammatory cells [58] . The study of antibiotic-mediated microbiota reduction and subsequent effects on pancreatic, colon, and melanoma tumor models revealed that microbiota depletion increases IFNγ producing T cell and reduces IL17A and IL10 producing T cell and reduces tumor burden in all models except Rag1-knockout mice [59] . IL-17 and IL-10 are considered as major immune regulators in a variety of carcinogenesis with a range of observations [60, 61] , the role of microbiota in regulating these cytokines indicate towards their involvement in this process. Targeting of harmful microbiota components through antibiotics further boosts immune system and aids in suppression of cancer development. Several other bacteria are studied for their potential involvement in cancer with varied mechanisms. Among these, Escherichia coli is also found to be linked with colorectal cancer with a range of observations. It is found that increase of genotoxin producing microorganisms including E. coli can contribute to chronic inflammationmediated colorectal cancer. It is suggested that colibactin induced host DNA damage contribute to colorectal cancer etiology [62] . Moreover, mutY is a DNA repair gene in E. coli and its human homolog MUTYH is linked with colorectal cancer. This homology of both DNA repair 

The intracellular growth without extracellular cell to cell spread makes it an ideal vector for anticancer therapy. Acts as an immunomodulator to enhance anticancer T cell immune response [98, 99] 2 Bifidobacterium spp. Biotrasformation and production of antitumor metabolites from nutrition and drugs, competitive advantage in cancer microenvironment by exclusion of harmful microbiota and pathogens, modulation of cancer-associated cytokines and genes [100] 3 Salmonella typhimurium Attenuated bacterium is suggested as a delivery vehicle for anticancer therapy due to selective tumor targeting and anticancer response [101] 4

Streptococcus pyogenes Direct tumor cell lysis and activation of immune response by bacterial components leads to cancer cell death [102] 5

Clostridium novyi Activation of host antitumor immune response and direct destruction of tumor cell. Works on hypoxic area (which is generally difficult to treat with conventional radio and chemotherapy) due to anaerobic nature of bacteria [103, 104] 6

Bacillus calmette Guerin Used as immunotherapy for prevention of cancer relapse and progression. Elevate the level of IL-2 and mediate anticancer activity by type 1 immune response [105] 7

Produce several metabolites such as, extracellular metalloproteinase serralysin, and prodigiosin with anticancer potential [106, 107] 8

Corynebacterium diptheriae Diptheria exotoxin possess antitumor activity and used as a immunotoxins consisting toxin with additional targeting element [108] genes and intracellular localization of E. coli in colonic epithelium during chronic inflammation raises suspicion that both DNA repair homologous proteins can compete and affect host cell DNA repair and therefore hypothesized for E. coli-mediated colorectal cancer [16] . Another wellstudied bacteria for its involvement in carcinogenesis is Fusobacterium nucleatum, which is found to be implicated in colorectal cancer [63, 64] , gastric cancer [65] , esophageal cancer [66] , and head and neck squamous cell carcinoma [67] . F. nucleatum is having certain regulators known to mediate cancerous changes, for example Fap2 protein of F. nucleatum interacts with TIGIT receptor present on natural killer (NK) cells and inhibit their cytotoxicity and subsequently contribute to tumor evasion [68] . Moreover, Fap2 also leads to Fusobacterium abundance in CRC which over-express Gal-GalNAc and binds to Fap2 protein, even though hematogenous route [69] and further contribute to its carcinogenic ability. Another F. nucleatum protein FadA bind to E-cadherin on CRC cells and induces β -catenin signaling leading to regulation of inflammatory and oncogenic response. This study also identified that synthetic peptide inhibit FadA-E cadherinmediated CRC progression, inflammatory and oncogenic response and the level of FadA is also found to be higher in adenomas and adenocarcinoma than normal colon tissues [70] . The role of F. nucleatum in carcinogenesis is also reviewed and it has been suggested that its LPS can stimulate inflammatory cytokines leading to proinflammatory environment promoting tumor progression. The activation of ß-catenin signaling also activates Wnt signaling, Myc and cyclin D1 oncogenes contributing to cancer cell proliferation [71] . Another anaerobic bacterium Peptostreptococcus anaerobius selectively enriched in CRC microbiota. It is known to bind α2/β1 integrin (overexpressed on CRC cells) through putative cell wall binding repeat 2 (PCWBR2) surface protein present on bacteria. This interaction activate PI3K-Akt pathway through phospho-focal-adhesion kinase and stimulate increased cell proliferation, NF-kB activation and resultant proinflammatory events, such as interleukin-10, interferon-γ production and involvement of tumour-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), and granulocytic tumour-associated neutrophils (GTAM) [72] . The role of PI3K-Akt pathway is already suggested in several other microbes-associated cancer, such as Salmonella typhi is suggested to be involved in gallbladder carcinoma through this important pathway in addition to several other events [73] .

Enteotoxigenic Bacteroides fragilis (ETBF) is another bacterium which produces BF toxin (BFT) contributing to diarrhea, inflammatory bowel disease and colon cancer [74] . BFT produced by ETBF promotes inflammation through expression of cyclooxygenase (COX-2) releasing PGE2, activation of STAT3 signaling, and degradation of E-cadherin leading to upregulation of spermine oxidase-mediated DNA damage and carcinogenesis [75] .

Porphyromonas gingivalis is found to be associated with increased pancreatic cancer risk. Though it is an oral bacteria but detected in human pancreatic cancer as an intracellular pathogen. Its intracellular residence is enhanced by hypoxia, which is an important characteristic of pancreatic cancer and intracellular persistence is directly related to increased tumor cell proliferation [76] . Some studies have indicated role of chronic Mycobacterium tuberculosis (Mtb) infection in lung cancer through induction of several mechanisms including inflammation [77] . It is demonstrated that Mtb induces lung specific cell dysplasia, squamous cell carcinoma. The Mtb-infected macrophages induces DNA damage in surrounding tissue and produces epiregulin (an epidermal growth factor) contributing to tumorigenesis [78] . Salmonella enterica subsp. enterica serovar Typhi (S. typhi) is also found to be linked with gall bladder carcinoma risk with its ability to form biofilm and production of toxin contributing to DNA damage and cell cycle alterations [79] . Similarly, Helicobacter pylori is a well-known bacteria recognized as carcinogen and contribute to carcinogenesis through multiple mechanisms. H. pylori induces inflammation, DNA damage, DNA methylation, epithelial mesenchymal transition, and direct cell proliferation through activation of various signaling events, like PI3K/Akt pathway [80] . These organisms are linked to certain diseases and do not form components of general microbiota, but their potentials in carcinogenesis provide indication of bacterial involvement in cancer progression.

The role of microbiota in cancer is a relatively new aspect and need more investigations to understand collective effect of microbiota components in carcinogenesis process. Discrete studies are arising understanding role of individual microbiota component in cancer progression, prevention and management. In contrast, microbiota works as an ecosystem where each component is contributing to the process of affecting normal host physiology. Therefore, we need a model to understand contribution of microbiota as a community in addition to understanding role of individual microbiota component in carcinogenic process. The recent development of next generation sequencing technologies with omics analysis can help us to develop such models. Several recent approaches such as microarray, metagenomics analysis coupled with meta-trascriptomics analyses can indicate about microbial community composition in addition to their influence on normal host physiology and subsequent effects on carcinogenesis. System biological approaches of host-pathogen interactions analyses can also aid in these objectives through reducing time and labor required for such large-scale analyses of microbial community and their influence on disease progression [81] [82] [83] . Nonetheless, current findings and observations are indicating that microbiota can contribute to carcinogenesis through a variety of mechanisms and understanding of these mechanisms can help us to plan suitable preventive and therapeutic strategy for cancer. In addition, mechanistic identification of anticancer activity of microbes is paving the way to develop suitable therapeutics for management of cancer. Summarily, identification of mechanistic implication of microbiota in carcinogenesis and its prevention can provide us interventions for prevention and management of a variety of cancer.

Author contributions AAK conceptualization; data curation; formal analysis; project administration; resources; visualization; roles/writing-original draft; writing-review and editing, ATS data curation; formal analysis; investigation; roles/writing-review and editing, HS conceptualization; data curation; formal analysis; roles/writing-writing-review and editing, PC formal analysis; project administration; resources; supervision; validation; roles/writing-review and editing.

Funding None.

Ethical approval Not applicable.

Data availability All relevant data are available with manuscript.

Neurological and cognitive significance of probiotics: a holy grail deciding individual personality

Effects of probiotics, prebiotics, and synbiotics on human health

Gut microbiota and cardiovascular disease: opportunities and challenges

Gut microbiome: profound implications for diet and disease

Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome

Normal to cancer microbiome transformation and its implication in cancer diagnosis

Current status of probiotics for prevention and management of gastrointestinal cancers

Gut microbiota and probiotics: current status and their role in cancer therapeutics

Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities

The search for infectious causes of human cancers: where and why

Helicobacter pylori and gastric cancer: a state of the art review

Proteinprotein interactions of HPV-Chlamydia trachomatis-human and their potential in cervical cancer

Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli

Alshamsan A. Computational prediction of Escherichia coli proteins host subcellular targeting and their implications in colorectal cancer etiology

In silico prediction of Escherichia coli proteins targeting the host cell nucleus, with special reference to their role in colon cancer etiology

is mutY a culprit?

Salmonella typhi and gallbladder cancer: report from an endemic region

Cancer-promoting effects of microbial dysbiosis

Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking

Microbiota disbiosis is associated with colorectal cancer

Microbial dysbiosis is associated with human breast cancer

Metabolic activities of the gut microflora in relation to cancer

Effects of soybean oligosaccharides on the human gut microflora in in vitro culture

Fecal microbiota transplantation: in perspective

Gut microbiota-dependent modulation of energy metabolism

Erythroid differentiation regulator-1 induced by microbiota in early life drives intestinal stem cell proliferation and regeneration

Effects of dietary fiber on mucosal growth and cell proliferation in the small intestine of the rat: a comparison of oat bran, pectin, and guar with total fiber deprivation

Intestinal mucosal atrophy and adaptation

Stimulatory effect of short chain fatty acids on the epithelial cell proliferation in rat large intestine

Control of intestinal epithelial proliferation and differentiation: the microbiome, enteroendocrine L cells, telocytes, enteric nerves, and GLP

Bacterial nucleomodulins and cancer: an unresolved enigma

How bacteria-induced apoptosis of intestinal epithelial cells contributes to mucosal inflammation

The microbiota influences cell death and microglial colonization in the perinatal mouse brain

Probiotic bacterium prevents cytokineinduced apoptosis in intestinal epithelial cells

Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth

Cancer-associated tolllike receptor modulation and insinuation in infection susceptibility: association or coincidence?

Toll-like receptor signaling in cell proliferation and survival

Gut microbiota, chemotherapy and the host: the influence of the gut microbiota on cancer treatment. Ecancermedicalscience

Pharmacomicrobiomics: a novel route towards personalized medicine?

A two-way interaction between methotrexate and the gut microbiota of male sprague-dawley rats

The influence of gut microbiota dysbiosis to the efficacy of 5-fluorouracil treatment on colorectal cancer

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide

Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management

The role of gut microbiota in cancer treatment: friend or foe?

Biotechnological advancement in isolation of anti-neoplastic compounds from natural origin: a novel source of L-asparaginase

Anticancer activity of bacterial proteins and peptides

Exploring the emerging role of the microbiome in cancer immunotherapy

The role of gut microbiota in SARS-CoV-2 infection: focus on angiotensin-converting enzyme 2

Probiotics in prevention and treatment of COVID-19: current perspective and future prospects

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Small but mighty: selected commensal bacterial species determine the effectiveness of anticancer immunotherapies

Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

An address on the value of pathological experiments

Microbiome, inflammation, and cancer

Linking the human gut microbiome to inflammatory cytokine production capacity

Mechanisms by which the gut microbiota influences cytokine production and modulates host inflammatory responses

Gut microbiota promotes tumor growth in mice by modulating immune response

The role of interleukin-17 in tumor development and progression

The paradoxical role of IL-10 in immunity and cancer

Intestinal inflammation targets cancer-inducing activity of the microbiota

High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients

Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma

Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan

Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis

Microbial communities associated with primary and metastatic head and neck squamous cell carcinoma-a high Fusobacterial and low Streptococcal signature

Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack

Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc

Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin

Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity

Salmonella enterica subsp. enterica hostpathogen interactions and their implications in gallbladder cancer

Enterotoxigenic Bacteroides fragilis: a possible etiological candidate for bacterially-induced colorectal precancerous and cancerous lesions. Front Cell Infect Microbiol

The mechanism of Bacteroides fragilis toxin contributes to colon cancer formation

Intracellular Porphyromonas gingivalis promotes the tumorigenic behavior of pancreatic carcinoma cells

Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study

Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control

Biofilm producing Salmonella typhi: chronic colonization and development of gallbladder cancer

Molecular mechanisms of gastric cancer initiation and progression by Helicobacter pylori

Inter-kingdom prediction certainty evaluation of protein subcellular localization tools: microbial pathogenesis approach for deciphering host microbe interaction

COVID-2019-associated overexpressed Prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak

Comparative host-pathogen proteinprotein interaction analysis of recent coronavirus outbreaks and important host targets identification

Chlamydia psittaci in ocular adnexa MALT lymphoma: a possible role in lymphomagenesis and a different geographical distribution

Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbialtargeted therapy

Possible role of Porphyromonas gingivalis in orodigestive cancers

Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression

Molecular mechanism of Helicobacter pyloriinduced gastric cancer

Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway

Chlamydia pneumoniae and lung cancer: epidemiologic evidence

The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role

Streptococcus gallolyticus abrogates anticarcinogenic properties of tannic acid on low-passage colorectal carcinomas

Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms

The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management

The association between fecal enterotoxigenic B. fragilis with colorectal cancer

Citrobacter infection and wnt signaling

Cervical cancer induction enhancement potential of Chlamydia trachomatis: a systematic review

Listeria monocytogenes as a vector for anti-cancer therapies

Listeria monocytogenes cancer vaccines: bridging innate and adaptive immunity

Antitumor mechanisms of Bifidobacteria

Salmonella typhimurium as an anticancer therapy: recent advances and perspectives

Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model

Clostridium novyi-NT in cancer therapy

Novel insights into the role of Clostridium novyi-NT related combination bacteriolytic therapy in solid tumors

The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2

Purification and study of anti-cancer effects of Serratia marcescens serralysin

Biological potential and mechanism of prodigiosin from Serratia marcescens Subsp. lawsoniana in human choriocarcinoma and prostate cancer cell lines

Targeted diphtheria toxin-based therapy: a review article